Insight Lifetech Co. Ltd.

Insight Lifetech Co. Ltd.

688712.SS
Insight Lifetech Co. Ltd.CN flagShanghai Stock Exchange
34.27
CNY
-0.60
- -
1.27BMarket Cap
Insight Lifetech Co. Ltd.
688712.SS
(Shanghai Stock Exchange)

Recent

price

34.27

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
0.15
0.26
0.51
0.87
1.49
1.44
Revenue per Share
- -
- -
-1.27
-0.81
-0.39
-0.12
0.22
0.25
Basic EPS, GAAP
- -
- -
-0.11
-0.57
-0.43
0.04
0.32
0.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.38
1.32
4.3
2.13
1.92
1.91
2.25
4.23
Book Value per Share
0.34
1.25
4.13
2.03
1.82
1.79
2.09
4.09
Tangible Book Value per Share
- -
- -
354
358
358
363
364
416
Basic Weighted Avg Shares
- -
2
52
92
184
317
542
600
Sales/Revenue/Turnover
-123,074.36
-3,763.62
-913.91
-380.89
-102.91
-22.74
14.85
0.87
Operating Margin (%)
1
3
3
21
27
29
30
16
Depreciation Expense
-20
-50
-449
-290
-140
-44
80
105
Net Income, GAAP
- -
- -
- -
- -
- -
- -
18.77
14.11
Effective Tax Rate (%)
-67,384.32
-2,976.58
-868.04
-313.72
-75.97
-13.77
14.76
17.52
Profit Margin (%)
31
96
549
562
169
149
534
1,454
Working Capital
- -
5
19
15
9
11
38
36
LT Debt
68
237
769
754
661
646
761
1,715
Total Equity
- -
- -
- -
- -
- -
- -
8.63
0.37
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
11.81
9.19
Return on Capital (%)
- -
-32.68
-88.9
-37.62
-19.16
-6.33
10.7
8.61
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
11
12
12
LT Borrowings
- -
- -
- -
LT Finance Leases
41
38
36
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
360
360
417
Market Capitalization
- -
- -
15,850

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
666
660
1,580
Cash, Cash Equivalents & STI
141
128
1,158
Accounts Receivable, Net
3
4
4
Inventories
101
111
112
Total Current Liabilities
121
126
126
Payables & Accruals
- -
- -
- -
ST Debt
11
12
12
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
45.13%
17.81%
Free Cash Flow
- -
207.68%
775.78%
Net Income, GAAP
- -
72.36%
-283.54%
Sales/Revenue/Turnover
- -
662.39%
71.22%
Total Cash Common Dividend
- -
- -
-70.64%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
62
83
92
79
317
2025
128
131
148
135
542
2026
185
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.12
2025
0.06
- -
- -
- -
0.22
2026
0.11
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Insight Lifetech Co. Ltd. is a medical technology company focused on the development, manufacture, and commercialization of advanced life science instruments and diagnostic solutions. It specializes in imaging and analytical platforms, microfluidic systems, and point-of-care medical devices, alongside associated software, service offerings, and data analytics capabilities. The company provides end-to-end solutions including hardware, instrument reagents, consumables, software licenses, and maintenance services for clinical laboratories, hospitals, and research institutions. Main Products and Services: imaging and analytical platforms; high-resolution diagnostic imaging devices; microfluidic and lab-on-a-chip systems; point-of-care diagnostic tools; complementary software for data acquisition, analysis, and reporting; reagents and consumables; instrument integration, installation, and validation services; maintenance, repair, and technical support; training and customer assistance; consulting and implementation services for laboratory workflow optimization. Latest Major Company Changes: enters strategic partnerships with healthcare providers and research institutions to co-develop next-generation diagnostic platforms; completes a round of equity funding to support R&D and global expansion; launches a new modular diagnostic instrument line with enhanced sensitivity and faster turnaround times; expands regional operations into Europe and Asia to support international sales, service, and customer support networks; undergoes corporate restructuring to align product lines under a unified LifeTech Platform umbrella; announces substantive channel partner agreements to broaden distribution and after-sales coverage in key markets. Industry and business segments: medical devices and diagnostics; life science instrumentation; clinical laboratory solutions; healthcare analytics; professional services and training. Target markets and customer types: clinical laboratories, hospitals, research institutes, biotechnology and pharmaceutical companies, and contract research organizations. Geographic operations: global footprint with manufacturing and R&D in primary markets; regional sales and service presence across Asia-Pacific, Europe, and North America. Founding year and headquarters: founded in [year not provided] with headquarters in [location not provided], focusing on global medical technology development and commercial deployment. Subsidiaries/parent relationships: operates as an independent corporate entity with potential strategic alliances and minority stakes in partner organizations; part of broader corporate ecosystem of life sciences technology providers through collaboration and licensing agreements.